Although GLP-1 receptor agonists like semaglutide show potential for treating SMS-related obesity and behavior, the variability in response between different forms (injectable vs oral and optimal dosage) indicates the need for further research to optimize treatment protocols and better understand their effects in genetic obesity syndromes. Here, GLP1R is linked to Obesity.